Free Trial

Ultragenyx Pharmaceutical (RARE) Earnings Date, Estimates & Call Transcripts

→ Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad)
Free RARE Stock Alerts
$44.24
+0.39 (+0.89%)
(As of 04/26/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
May. 2
After Market Closes
Confirmed
Actual EPS
(Feb. 15)
-$1.52 Beat By $0.13
Consensus EPS
(Feb. 15)
-$1.65
Read Call Transcript
Listen to Call
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

RARE Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RARE Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Ultragenyx Pharmaceutical Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20242($1.49)($1.44)($1.47) 
Q2 20242($1.40)($1.37)($1.39) 
Q3 20242($1.38)($1.22)($1.30) 
Q4 20242($1.37)($1.19)($1.28) 
FY 20248($5.64)($5.22) ($5.43)

RARE Earnings Date and Information

Ultragenyx Pharmaceutical last released its earnings results on February 15th, 2024. The biopharmaceutical company reported ($1.52) EPS for the quarter, topping analysts' consensus estimates of ($1.65) by $0.13. The business earned $127.39 million during the quarter, compared to the consensus estimate of $119.38 million. Its quarterly revenue was up 23.3% on a year-over-year basis. Ultragenyx Pharmaceutical has generated ($8.33) earnings per share over the last year (($8.33) diluted earnings per share). Earnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($6.36) to ($5.12) per share. Ultragenyx Pharmaceutical has confirmed that its next quarterly earnings report will be published on Thursday, May 2nd, 2024. Ultragenyx Pharmaceutical will be holding an earnings conference call on Thursday, May 2nd at 5:00 PM Eastern. Interested parties can register for or listen to the call..

Ultragenyx Pharmaceutical Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/2/2024
Confirmed)		-------  
2/15/2024Q4 2023($1.65)($1.52)+$0.13($1.52)$119.38 million$127.39 million    
11/2/2023Q3 2023($2.08)($2.23)($0.15)($2.23)$99.38 million$98.05 million
8/3/2023Q2 2023($2.11)($2.25)($0.14)($2.25)$107.10 million$108.30 million    
5/4/2023Q1 2023($1.97)($2.33)($0.36)($2.33)$103.90 million$100.50 million    
2/16/2023Q4 2022($2.03)($2.16)($0.13)($2.16)$105.11 million$103.35 million    
11/2/2022Q3 2022($2.29)($2.43)($0.14)($1.36)$98.76 million$90.70 million
7/28/2022Q2 2022($1.72)($2.26)($0.54)($2.26)$87.33 million$89.34 million    
5/5/2022Q1 2022($1.76)($2.19)($0.43)($2.19)$84.25 million$79.94 million    
2/10/2022Q4 2021($1.32)($1.79)($0.47)($1.79)$83.68 million$83.39 million    
11/2/2021Q3 2021($1.43)($1.08)+$0.35($1.08)$78.16 million$81.65 million    
8/1/2021Q2 2021($1.28)($1.81)($0.53)($1.09)$85.88 million$86.98 million    
5/4/2021Q1 2021($1.25)($2.03)($0.78)($2.03)$77.21 million$99.40 million  

Ultragenyx Pharmaceutical Earnings - Frequently Asked Questions

When is Ultragenyx Pharmaceutical's earnings date?

Ultragenyx Pharmaceutical has confirmed that its next quarterly earnings data will be published on Thursday, May 2nd, 2024. Learn more on RARE's earnings history.

Did Ultragenyx Pharmaceutical beat their earnings estimates last quarter?

In the previous quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) reported ($1.52) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.65) by $0.13. Learn more on analysts' earnings estimate vs. RARE's actual earnings.

How can I listen to Ultragenyx Pharmaceutical's earnings conference call?

The conference call for Ultragenyx Pharmaceutical's latest earnings report can be listened to online. Listen to Conference Call

How can I read Ultragenyx Pharmaceutical's conference call transcript?

The conference call transcript for Ultragenyx Pharmaceutical's latest earnings report can be read online. Read Transcript

How much revenue does Ultragenyx Pharmaceutical generate each year?

Ultragenyx Pharmaceutical (NASDAQ:RARE) has a recorded annual revenue of $434.25 million.

How much profit does Ultragenyx Pharmaceutical generate each year?

Ultragenyx Pharmaceutical (NASDAQ:RARE) has a recorded net income of -$606.64 million. RARE has generated -$8.33 earnings per share over the last four quarters.

What is Ultragenyx Pharmaceutical's EPS forecast for next year?

Ultragenyx Pharmaceutical's earnings are expected to grow from ($6.36) per share to ($5.12) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:RARE) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
Colonial Metals
These AI trades triggered this morning (545% return)
Prosper Trading Academy
He Is Giving Away Bitcoin
Crypto Swap Profits
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
The World's First "$20 Trillion Drug?"
Behind the Markets
Emergency: Biden's $20 Trillion Mistake Could Cost YOU!
GoldenCrest Metals
Fed launches fourth dollar overhaul
Stansberry Research
Biden out June 13; Kamala won’t replace him?
Paradigm Press